echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > After Varenicline, Hausen Pharmaceuticals is expected to win the first imitation of Cabozantinib tablets

    After Varenicline, Hausen Pharmaceuticals is expected to win the first imitation of Cabozantinib tablets

    • Last Update: 2021-08-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, the listing application (relevant acceptance number: CYHS2000663/664) of the 3 generic generic drug "Carbotinib Malate Tablets" in Hausen Pharmaceuticals changed its status in NMPA to "Under Approval", and it is expected that it will be formally approved in the near future


    Cabozantinib is a multi-target small molecule tyrosine kinase inhibitor.


    Cometriq was approved by the FDA in November 2012 for the treatment of unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC)


    Cabometyx was used by the FDA in April 2016 for patients with advanced renal cell carcinoma (RCC) who had previously failed vascular endothelial growth factor (VEGF) targeted therapy.


    In addition, the original research Cabozantinib has also been developed for the treatment of non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer, bowel cancer and other cancers


    The original research Cabozantinib was developed by Exelixis


    In China, the original Cabozantinib has not yet been approved, and the original Cabozantinib tablet is in Phase 3 clinical trials, and its indication is combined with Atezolizumab for advanced hepatocellular carcinoma that has not previously received systemic anti-cancer treatment


    At present, a number of domestic companies have set up the cabozantinib generic drug market.


    Hausen Pharmaceuticals is the first domestic company to submit an application for the listing of a generic version of Cabozantinib Malate Tablets.


    As of now, Hausen Pharmaceuticals has won the first imitation of Varenicline in 2021


    In addition, the 2021 class of drugs Stockhausen medicine Amy tenofovir sheet (also called: Amy Diaminodiphenol tenofovir tablets) are approved domestic, for adults with chronic indications


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.